You just read:

Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

News provided by

Soligenix, Inc.

May 03, 2017, 06:00 ET